Clinical Trial Update: A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of repotrectinib in combination with other anticancer therapies for KRAS-mutant solid tumors has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras Mutation-related Tumors
• Solid Tumor

Drugs mentioned

• Repotrectinib (repotrectinib)

Snippet

Sponsor: Turning Point Therapeutics, Inc. | Conditions: KRAS Mutation-Related Tumors, Metastatic Solid Tumor | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-04-02